InvestorsHub Logo
Followers 16
Posts 1698
Boards Moderated 0
Alias Born 09/29/2016

Re: None

Saturday, 02/03/2024 9:43:46 AM

Saturday, February 03, 2024 9:43:46 AM

Post# of 694213
Deal-hungry Merck plans more phase 3 launches than in 2023

Davis reiterated that Merck is interested in deals between $1 billion and $15 billion, with the $10 billion-plus range being the sweet spot.

All these moves are part of Merck’s larger diversification strategy to assuage investor concerns about Keytruda’s 2028 patent expiration.
“We do continue to believe we need more and we will continue to prioritize business development,” Davis said on the Thursday earnings call.

Recent acquisitions and partnerships contributed to Merck’s ballooning R&D spend in 2023, which exceeded a whopping $30 billion in GAAP expenses.

scroll down
https://www.fiercebiotech.com/biotech/merck-plans-more-phase-3-launches-2023-while-voracious-bd-appetite-remains
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News